Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 87% · stale
- Computed at
- 2026-10-21T06:30:51.312418+00:00
- Claimed
- 55
- Reported
- 55
- Verified
- 55
- Gap
- 0
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed and verified align
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-10-21
An approved treatment option for its specific previously treated ROS1-positive NSCLC indication.
- Why
- FDA-reviewed evidence demonstrates durable responses in a subset of patients, with significant safety monitoring requirements and limited postapproval experience.
- Next
- Evaluate use within the approved label through oncology care; follow longer-term safety, comparative outcomes and any future first-line regulatory decision.
Constraints
Blockers
- ROS1 testing and prior-treatment eligibility
- Significant toxicity monitoring and drug-interaction management
- Limited comparative and long-term postmarketing evidence
- First-line indication remains unapproved
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 5
- Tier 2
- 3
- Tier 3
- 0
- Supports
- 5
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-09-14
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-07-23 Reading moved from mature to mature.
- 2026-09-22 Reading moved from mature to mature.
- 2026-09-30 Reading moved from mature to ready.